Consolidated Financial Results
for the Six Months Ended August 31, 2025
(JGAAP)

October 9, 2025

Name of company: SUGI Holdings Co., Ltd. Stock exchange listing: Tokyo, Nagoya
Stock code: 7649 Company website: https://www.sugi-hd.co.jp/
Representative: Katsunori Sugiura, Representative Director & President
Contact: Makoto Kasai, Executive Managing Officer Responsible for Corporate Planning and Finance Phone: +81-562-45-2744
Scheduled filing date of semi-annual report: October 14, 2025 Scheduled start date of dividend payment: November 5, 2025
Supplementary documents to the financial results: Available
Financial results briefing: Scheduled (for securities analysts and institutional investors)

(All figures are rounded down to the nearest million yen)

1. Consolidated Earnings for the Second Quarter (First Half) Ended August 31, 2025

(1) Consolidated operating results (Percentage figures indicate year-on-year change)

	Net Sales		EBITDA		Operating Income		Ordinary Income		Profit Attributable to Owners of Parent	
	¥ million	%	¥ million	%	¥ million	%	¥ million	%	¥ million	%
Six months ended August 31, 2025	500,172	20.9	33,528	19.0	23,696	16.8	24,236	12.9	28,616	119.1
Six months ended August 31, 2024	413,809	12.9	28,167	17.7	20,286	17.3	21,468	18.4	13,059	27.2

Comprehensive income Six months ended August 31, 2025: ¥29,167 million (130.7%)
Six months ended August 31, 2024: ¥12,641 million (22.8%)

	Basic Earnings per Share	Diluted Earnings per Share
	¥	¥
Six months ended August 31, 2025	158.13	-
Six months ended August 31, 2024	72.17	-

Note: EBITDA = Operating income + Depreciation + Amortization of goodwill

(2) Consolidated financial position

	Total Assets	Net Assets	Equity Ratio	Net Assets per Share
	¥ million	¥ million	%	¥
As of August 31, 2025	554,801	276,292	49.8	1,526.71
As of February 28, 2025	495,116	250,704	50.6	1,385.37

(Reference) Shareholders' equity As of August 31, 2025 276,276 ¥ million
As of February 28, 2025 250,704 ¥ million

2. Dividends

	Annual Dividends				
	End of 1Q	End of 2Q	End of 3Q	Year-end	Total
	¥	¥	¥	¥	¥
FY2025/2	-	15.00	-	20.00	35.00
FY2026/2	-	15.00			
FY2026/2 (forecast)			-	20.00	35.00

Revisions to the latest dividend forecast: None

3. Consolidated Earnings Forecast for FY2026/2 (the period from March 1, 2025 to February 28, 2026)
(Percentage figures indicate year-on-year change)

	Net Sales		EBITDA		Operating Income		Ordinary Income		Profit Attributable to Owners of Parent		Basic Earnings per Share
	¥ million	%	¥ million	%	¥ million	%	¥ million	%	¥ million	%	¥
Full year	1,005,000	14.5	70,000	15.8	49,000	15.1	50,500	20.3	44,200	72.1	244.24

Revisions to the latest earnings forecast: None

Notes

(1) Significant changes in scope of consolidation during the period: Occurred
Newly included: None   Excluded: I&H Co., Ltd.
On March 1, 2025, we performed an absorption-type merger, with Sugi Pharmacy Co., Ltd. as the surviving company and I&H Co., Ltd. dissolving.

(2) Special accounting treatments for consolidated interim financial statements: Not adopted

(3) Changes in accounting policies, changes in accounting estimates, and restatements
(i) Changes in accounting policies due to revisions to accounting standards: Yes
(ii) Changes in accounting principles other than those in (i) above: None
(iii) Changes in accounting estimates: None
(iv) Restatements: None

(4) Number of shares outstanding (common stock)

(i) Number of shares outstanding at the end of the period (including treasury shares)	FY2026/2 1H	189,992,514 shares	FY2025/2	189,992,514 shares
(ii) Number of treasury shares at the end of the period	FY2026/2 1H	9,019,577 shares	FY2025/2	9,026,618 shares
(iii) Average number of shares during the period (1H)	FY2026/2 1H	180,968,958 shares	FY2025/2 1H	180,961,299 shares